Latest news with #NicolasPauillac
Business Insider
30-05-2025
- Business
- Business Insider
B.R.A.I.N. Biotechnology Research and Information Network (0RFI) Receives a Buy from Kepler Capital
In a report released on May 28, Nicolas Pauillac from Kepler Capital maintained a Buy rating on B.R.A.I.N. Biotechnology Research and Information Network (0RFI – Research Report), with a price target of €7.00. The company's shares closed last Tuesday at €2.09. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Pauillac covers the Healthcare sector, focusing on stocks such as COSMO Pharmaceuticals N.V., Sandoz Group Ltd, and OSE Immunotherapeutics SA. According to TipRanks, Pauillac has an average return of 11.7% and a 52.00% success rate on recommended stocks. B.R.A.I.N. Biotechnology Research and Information Network has an analyst consensus of Moderate Buy, with a price target consensus of €8.00.
Business Insider
24-05-2025
- Business
- Business Insider
Kepler Capital Keeps Their Buy Rating on OSE Immunotherapeutics SA (6OP)
Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on OSE Immunotherapeutics SA (6OP – Research Report) on May 22 and set a price target of €12.50. The company's shares closed last Wednesday at €5.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Pauillac is ranked #1271 out of 9536 analysts. OSE Immunotherapeutics SA has an analyst consensus of Moderate Buy, with a price target consensus of €13.25, a 123.44% upside from current levels. In a report released on May 7, H.C. Wainwright also maintained a Buy rating on the stock with a €14.00 price target.
Business Insider
18-05-2025
- Business
- Business Insider
Kepler Capital Reaffirms Their Buy Rating on Affluent Medical SA (0JZ)
In a report released on May 16, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Affluent Medical SA (0JZ – Research Report), with a price target of €3.80. The company's shares closed last Friday at €1.42. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Pauillac is ranked #1649 out of 9519 analysts. Affluent Medical SA has an analyst consensus of Moderate Buy, with a price target consensus of €3.80.
Business Insider
15-05-2025
- Business
- Business Insider
Kepler Capital Reaffirms Their Buy Rating on Eckert & Ziegler Strahlen und Medizintechnik (0NZY)
In a report released on May 13, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Eckert & Ziegler Strahlen und Medizintechnik (0NZY – Research Report), with a price target of €60.30. The company's shares closed last Friday at €39.74. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Pauillac is ranked #1649 out of 9519 analysts. Currently, the analyst consensus on Eckert & Ziegler Strahlen und Medizintechnik is a Moderate Buy with an average price target of €63.15.
Business Insider
27-04-2025
- Business
- Business Insider
Kepler Capital Sticks to Their Buy Rating for BB Biotech (0JYO)
Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on BB Biotech (0JYO – Research Report) on April 25 and set a price target of CHF66.00. The company's shares closed last Friday at CHF28.45. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. According to TipRanks, Pauillac is a 4-star analyst with an average return of 7.4% and a 40.85% success rate. BB Biotech has an analyst consensus of Moderate Buy, with a price target consensus of CHF66.00. The company has a one-year high of CHF43.95 and a one-year low of CHF24.50. Currently, BB Biotech has an average volume of 2,676.
